A1 Refereed original research article in a scientific journal
The protective PLCγ2-P522R variant mitigates Alzheimer’s disease-associated pathologies by enhancing beneficial microglial functions
Authors: Takalo, Mari; Jeskanen, Heli; Rolova, Taisia; Kervinen, Inka; Hellén, Marianna; Heikkinen, Sami; Koivisto, Hennariikka; Jokivarsi, Kimmo; Müller, Stephan A.; Koivumäki, Esa-Mikko; Mäkinen, Petra; Juopperi, Sini-Pauliina; Willman, Roosa-Maria; Sinisalo, Rosa; Hoffmann, Dorit; Jäntti, Henna; Peitz, Michael; Fließbach, Klaus; Kuulasmaa, Teemu; Natunen, Teemu; Kemppainen, Susanna; Poutiainen, Pekka; Leinonen, Ville; Malm, Tarja; Martiskainen, Henna; Ramirez, Alfredo; Haapasalo, Annakaisa; Lichtenthaler, Stefan F.; Tanila, Heikki; Haass, Christian; Rinne, Juha; Koistinaho, Jari; Hiltunen, Mikko
Publisher: Springer Science and Business Media LLC
Publishing place: LONDON
Publication year: 2025
Journal: Journal of Neuroinflammation
Journal name in source: Journal of Neuroinflammation
Journal acronym: J NEUROINFLAMM
Article number: 64
Volume: 22
Issue: 1
Number of pages: 30
eISSN: 1742-2094
DOI: https://doi.org/10.1186/s12974-025-03387-6
Web address : https://doi.org/10.1186/s12974-025-03387-6
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/491569347
Background: Phospholipase C gamma 2, proline 522 to arginine (PLCγ2-P522R) is a protective variant that reduces the risk of Alzheimer's disease (AD). Recently, it was shown to mitigate β-amyloid pathology in a 5XFAD mouse model of AD. Here, we investigated the protective functions of the PLCγ2-P522R variant in a less aggressive APP/PS1 mouse model of AD and assessed the underlying cellular mechanisms using mouse and human microglial models.
Methods: The effects of the protective PLCγ2-P522R variant on microglial activation, AD-associated β-amyloid and neuronal pathologies, and behavioral changes were investigated in PLCγ2-P522R knock-in variant mice crossbred with APP/PS1 mice. Transcriptomic, proteomic, and functional studies were carried out using microglia isolated from mice carrying the PLCγ2-P522R variant. Finally, microglia-like cell models generated from human blood and skin biopsy samples of PLCγ2-P522R variant carriers were employed.
Results: The PLCγ2-P522R variant decreased β-amyloid plaque count and coverage in female APP/PS1 mice. Moreover, the PLCγ2-P522R variant promoted anxiety in these mice. The area of the microglia around β-amyloid plaques was also increased in mice carrying the PLCγ2-P522R variant, while β-amyloid plaque-associated neuronal dystrophy and the levels of certain cytokines, including IL-6 and IL-1β, were reduced. These alterations were revealed through [18F]FEPPA PET imaging and behavioral studies, as well as various cytokine immunoassays, transcriptomic and proteomic analyses, and immunohistochemical analyses using mouse brain tissues. In cultured mouse primary microglia, the PLCγ2-P522R variant reduced the size of lipid droplets. Furthermore, transcriptomic and proteomic analyses revealed that the PLCγ2-P522R variant regulated key targets and pathways involved in lipid metabolism, mitochondrial fatty acid oxidation, and inflammatory/interferon signaling in acutely isolated adult mouse microglia and human monocyte-derived microglia-like cells. Finally, the PLCγ2-P522R variant also increased mitochondrial respiration in human iPSC-derived microglia.
Conclusions: These findings suggest that the PLCγ2-P522R variant exerts protective effects against β-amyloid and neuronal pathologies by increasing microglial responsiveness to β-amyloid plaques in APP/PS1 mice. The changes observed in lipid/fatty acid and mitochondrial metabolism revealed by the omics and metabolic assessments of mouse and human microglial models suggest that the protective effects of the PLCγ2-P522R variant are potentially associated with increased metabolic capacity of microglia.
Downloadable publication This is an electronic reprint of the original article. |
Funding information in the publication:
This work was supported by the Research Council of Finland, grant numbers 330178 (MT), 338182 (MH), and 355604 (HM), and 337530 and 357910 for Flagship InFLAMES (JR); Sigrid Juselius Foundation (MH, AH, JR); Strategic Neuroscience Funding of the University of Eastern Finland (SH, AH, MH); Strategic Funding of the University of Eastern Finland (MT); Doctoral Programme in Molecular Medicine of the University of Eastern Finland (HJ, IK and RMW); Finnish Governmental Research Grant for Turku University Hospital (JR); Alzheimer’s Association, ADSF-24–1284326-C (VL, TM, MH); JPco-fuND-2 ‘Multinational Research Projects on Personalized Medicine for Neurodegenerative Diseases’, grant numbers 334802 (PMG-AD; MH, JK, SL) and Bundesministerium für Bildung und Forschung Grant No. 01ED2007A (PREADAPT, AR); Biocenter Finland (KJ); Innovative Medicines Initiative 2 Joint Undertaking which receives support from the European Union’s Horizon 2020 research and innovation programme (ADAPTED Grant No. 115975, AR); the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy– ID 390857198, SL, CH); and by the Bundesministerium für Bildung und Forschung grant FKZ161L0214C, ClinspectM (SL).